Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Provecta IND cleared

Oct. 14, 2004

Allergan and Peplin discontinue PEP-005 collaboration

Oct. 14, 2004

ArTec prepares to review preclinical application for Tubercin with FDA

Oct. 14, 2004

In vivo tumor growth inhibition and apoptosis induced by human agonistic TRAIL receptor 2 antibody

Oct. 14, 2004

BDC-03 under development for cachexia

Oct. 14, 2004

Yondelis receives orphan drug status for soft tissue sarcoma

Oct. 14, 2004

Interim results of BrachySil phase IIa study in liver cancer patients

Oct. 14, 2004

Erbitux in phase III for NSCLC

Oct. 14, 2004

Simultaneous targeting of tumor proliferation and angiogenesis shows promising results in vivo

Oct. 14, 2004

Liposomal-encapsulated paclitaxel well tolerated in prostate cancer patients

Oct. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...